Vertex Pharmaceuticals Inc. Stock

The first five months of 2026 were rough on Vertex Pharmaceuticals (NASDAQ: VRTX). The biotech's shares moved in the wrong direction through early June. However, the drugmaker has bounced back in

Shares of Crinetics Pharmaceuticals (NASDAQ: CRNX) jumped 98% this week, according to data from S&P Global Market Intelligence. The upstart drugmaker is being acquired by Vertex Pharmaceuticals for

Vertex Pharmaceuticals (NASDAQ: VRTX) is a biotech company that has steadily delivered growth to investors, thanks to its dominance in cystic fibrosis (CF) treatment. The company's portfolio of CF

In the latest big-ticket deal in the pharmaceutical industry, Vertex Pharmaceuticals (NASDAQ:VRTX) and Crinetics Pharmaceuticals (NASDAQ:CRNX) announced in a joint press release that Vertex is

Vertex Pharmaceuticals (NASDAQ: VRTX) is making its biggest bet in years. On Monday, the company agreed to acquire Crinetics Pharmaceuticals (NASDAQ: CRNX) for $85 per share in cash. That works out

When a stock hits a 52-week high, that's a great sign the business is doing well. And when it hits a new all-time high, then you know the market is really excited about what's ahead for the

No stock has generated more buzz in recent weeks than Space Exploration Technologies (NASDAQ: SPCX), more commonly known as SpaceX. That's understandable, considering the space technology and

Choosing between Arcutis Biotherapeutics (NASDAQ:ARQT) and Vertex Pharmaceuticals (NASDAQ:VRTX) involves weighing a high-growth newcomer against a cash-generating giant. Both companies aim to

Choosing between a high-growth clinical-stage player and an established industry titan can be difficult for investors. This comparison examines Dyne Therapeutics (NASDAQ:DYN) and Vertex

Starting the week on an auspicious note, Vertex (NASDAQ: VERX) stock is rising this morning. Shares of the software company are bouncing higher after an analyst initiated coverage with a bullish

Deciding between CRISPR Therapeutics AG (NASDAQ:CRSP) and Vertex Pharmaceuticals (NASDAQ:VRTX) involves weighing high-growth gene-editing potential against a profitable, established leader. Both

Vertex Pharmaceuticals (NASDAQ: VRTX) and Eli Lilly (NYSE: LLY) are two leading drugmakers that dominate their respective core therapeutic areas. Vertex has a monopoly in the market for drugs that

CRISPR Therapeutics (NASDAQ: CRSP) has been anything but stable this year. Over the past six months, the stock has experienced sharp swings as the market attempts to determine whether CRISPR is

Pharmaceutical companies can offer investors huge returns if treatments under development become blockbuster drugs. Choosing between a speculative clinical-stage play and a dominant cash-flow engine

Gene-editing technology has moved from science fiction to clinical reality, forcing investors to choose between commercial leaders and early-stage innovators. Deciding between CRISPR Therapeutics AG

The gene-editing niche of the biotech industry is gaining momentum, as various companies focused on these techniques -- which allow scientists to alter patients' DNA to treat some diseases -- have

If you had invested $20,000 in Vertex Pharmaceuticals (NASDAQ: VRTX) in its IPO in 1991 and held onto its shares, you'd have over $1 million today, considering the company's strong 14% compound

Intuitive Surgical (NASDAQ: ISRG) and Vertex Pharmaceuticals (NASDAQ: VRTX) have posted excellent returns over the past 10 years, but they are encountering obstacles right now. Both healthcare